Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis
Twist Bioscience (Nasdaq: TWST) and bitBiome have announced a strategic collaboration, launching a joint Transaminase Enzyme Screening Kit. This kit contains 48 diverse transaminase enzymes for in-house screening and evaluation. The collaboration combines Twist's high-capacity DNA synthesis technology with bitBiome's proprietary database of over two billion microbe sequences.
The kit aims to provide labs and pharmaceutical companies with improved enzymes for biocatalysis, particularly for synthesizing active pharmaceutical ingredients (APIs). Transaminases are important in creating chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential 'green alternative' to conventional synthesis methods.
This partnership leverages bitBiome's diverse sequence database and Twist's large-scale DNA synthesis capabilities to create innovative solutions for the biomanufacturing industry.
Twist Bioscience (Nasdaq: TWST) e bitBiome hanno annunciato una collaborazione strategica, lanciando un Kit di Screening degli Enzimi Trasaminasi congiunto. Questo kit contiene 48 enzimi trasaminasi diversi per screening e valutazione in-house. La collaborazione combina la tecnologia di sintesi DNA ad alta capacità di Twist con il database proprietario di bitBiome che conta oltre due miliardi di sequenze microbiche.
Il kit ha l'obiettivo di fornire ai laboratori e alle aziende farmaceutiche enzimi migliorati per la biocatalisi, in particolare per la sintesi degli ingredienti farmaceutici attivi (API). Le trasaminasi sono importanti nella creazione di ammine chirali, preziosi mattoni per l'industria farmaceutica, offrendo una potenziale 'alternativa ecologica' ai metodi di sintesi convenzionali.
Questa partnership sfrutta il database di sequenze diversificate di bitBiome e le capacità di sintesi DNA su larga scala di Twist per creare soluzioni innovative per l'industria della biomanifattura.
Twist Bioscience (Nasdaq: TWST) y bitBiome han anunciado una colaboración estratégica, lanzando un Kit de Screening de Enzimas Transaminasas conjunto. Este kit contiene 48 enzimas transaminasas diversas para screening y evaluación interna. La colaboración combina la tecnología de síntesis de ADN de alta capacidad de Twist con la base de datos propietaria de bitBiome que cuenta con más de dos mil millones de secuencias microbianas.
El kit tiene como objetivo proporcionar a laboratorios y empresas farmacéuticas enzimas mejoradas para biocatalisis, especialmente para la síntesis de ingredientes farmacéuticos activos (API). Las transaminasas son importantes en la creación de aminas quirales, bloques de construcción valiosos para la industria farmacéutica, ofreciendo una potencial 'alternativa verde' a los métodos de síntesis convencionales.
Esta asociación aprovecha la diversa base de datos de secuencias de bitBiome y las capacidades de síntesis de ADN a gran escala de Twist para crear soluciones innovadoras para la industria de biomanufactura.
트위스트 바이오사이언스(Twist Bioscience)(NASDAQ: TWST)와 비트바이옴(bitBiome)이 전략적 협력을 발표하며 공동으로 아미노전이효소 스크리닝 키트를 출시했습니다. 이 키트에는 48가지 다양한 아미노전이효소가 포함되어 있으며, 내부 스크리닝 및 평가에 사용됩니다. 이번 협력은 트위스트의 대용량 DNA 합성 기술과 비트바이옴의 20억 개 이상의 미생물 염기서열 데이터베이스를 결합합니다.
이 키트는 실험실과 제약 회사에 생물 촉매를 위한 향상된 효소를 제공하여, 특히 활성 약물 성분(API)의 합성을 지원하는 것을 목표로 합니다. 아미노전이효소는 제약 산업에서 소중한 구성 요소인 키랄 아민을 생성하는 데 중요하며, 기존 합성 방법에 대한 '친환경 대안'을 제공합니다.
이 파트너십은 비트바이옴의 다양한 염기서열 데이터베이스와 트위스트의 대규모 DNA 합성 능력을 활용하여 생물 제조 산업을 위한 혁신적인 솔루션을 창출합니다.
Twist Bioscience (Nasdaq: TWST) et bitBiome ont annoncé une collaboration stratégique, lançant un Kit de Screening des Enzymes Transaminases commun. Ce kit contient 48 enzymes transaminases diverses pour un screening et une évaluation en interne. La collaboration associe la technologie de synthèse d'ADN à grande échelle de Twist à la base de données propriétaire de bitBiome comprenant plus de deux milliards de séquences microbiennes.
Le kit vise à fournir aux laboratoires et aux entreprises pharmaceutiques des enzymes améliorées pour la biocatalyse, particulièrement pour la synthèse des ingrédients pharmaceutiques actifs (API). Les transaminases jouent un rôle clé dans la création d'amines chirales, des éléments essentiels pour l'industrie pharmaceutique, offrant une 'alternative écologique' potentielle aux méthodes de synthèse conventionnelles.
Ce partenariat exploite la base de données de séquences diversifiées de bitBiome et les capacités de synthèse d'ADN à grande échelle de Twist pour créer des solutions innovantes pour l'industrie de la biomanufacturation.
Twist Bioscience (NASDAQ: TWST) und bitBiome haben eine strategische Zusammenarbeit angekündigt und ein gemeinsames Transaminase-Enzym-Screening-Kit auf den Markt gebracht. Dieses Kit enthält 48 verschiedene Transaminasen zur internen Screening und Bewertung. Die Zusammenarbeit kombiniert die Hochdurchsatz-DNA-Synthesetechnologie von Twist mit der proprietären Datenbank von bitBiome, die über zwei Milliarden Mikroben-Sequenzen umfasst.
Das Kit zielt darauf ab, Labors und Pharmaunternehmen verbesserte Enzyme für die Biokatalyse bereitzustellen, insbesondere zur Synthese von aktiven pharmazeutischen Inhaltsstoffen (APIs). Transaminasen sind wichtig für die Herstellung von chiralen Aminen, wertvollen Bausteinen der Pharmaindustrie, und bieten eine potenzielle 'grüne Alternative' zu herkömmlichen Synthesemethoden.
Diese Partnerschaft nutzt die vielfältige Sequenzdatenbank von bitBiome und die umfangreichen DNA-Synthesefähigkeiten von Twist, um innovative Lösungen für die Bioproduktionsindustrie zu schaffen.
- Launch of a joint Transaminase Enzyme Screening Kit with 48 diverse enzymes
- Collaboration combines Twist's DNA synthesis technology with bitBiome's database of over 2 billion microbe sequences
- Potential to improve biocatalysis processes for pharmaceutical ingredient synthesis
- Offers a 'green alternative' to conventional chemical synthesis methods
- None.
Insights
The collaboration between Twist Bioscience and bitBiome to launch the Transaminase Enzyme Screening Kit is a significant development in the field of biocatalysis. This kit, featuring 48 diverse transaminase enzymes, has the potential to revolutionize the synthesis of chiral amines, important components in pharmaceutical manufacturing.
The partnership leverages Twist's high-capacity DNA synthesis technology and bitBiome's extensive microbe sequence database (bit-GEM), containing over 2 billion sequences. This combination allows for the identification and synthesis of novel, highly efficient enzymes that could significantly improve the production of active pharmaceutical ingredients (APIs).
The move towards biocatalysis represents a "green alternative" to traditional chemical synthesis methods, potentially reducing environmental impact and production costs in the pharmaceutical industry. This could lead to more sustainable and cost-effective drug manufacturing processes, benefiting both companies and consumers in the long run.
While the immediate financial impact of this collaboration may not be substantial, it positions both Twist Bioscience (NASDAQ: TWST) and bitBiome strategically in the growing biocatalysis market. The global biocatalysis market is projected to reach
For Twist, this partnership expands its product portfolio and potentially opens up new revenue streams in the pharmaceutical and biotechnology sectors. It also demonstrates the company's ability to leverage its DNA synthesis technology in innovative ways, which could attract more partnerships and customers.
Investors should monitor the adoption rate of this screening kit and any subsequent products resulting from this collaboration. If successful, it could lead to increased revenue and market share for Twist in the biocatalysis space, potentially driving long-term growth and stock performance.
The Transaminase Enzyme Screening Kit represents a significant advancement in pharmaceutical manufacturing processes. Chiral amines are essential building blocks in many drugs and improving their synthesis can have far-reaching effects on drug development and production.
Key benefits for pharmaceutical companies include:
- Potential for more efficient and cost-effective API production
- Reduced environmental impact, aligning with growing sustainability demands
- Access to a diverse range of novel enzymes, potentially leading to new drug discoveries
However, adoption may face challenges such as regulatory hurdles and the need for process validation. Companies will need to weigh the potential benefits against the costs of implementing new biocatalytic processes. Nevertheless, this collaboration could spark a shift towards more sustainable and innovative pharmaceutical manufacturing methods industry-wide.
Transaminase enzymes catalyze the transfer of an amine group from an amine donor. Importantly, transaminases have emerged as an exciting option for the synthesis of chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential “green alternative” to conventional synthesis.
Pairing Twist Bioscience’s high-capacity synthesis technology with bitBiome’s one-of-a-kind proprietary database (bit-GEM) of over two billion microbe sequences enabled the creation of the innovative Transaminase Enzyme Screening Kit. This kit features a unique set of transaminases that can be used by labs and pharmaceutical companies to efficiently implement improved enzymes for biocatalysis, particularly for the synthesis of active pharmaceutical ingredients (APIs). Biocatalysis provides a viable alternative to conventional chemically synthesized processes used in the manufacturing of small molecule pharmaceuticals and other key ingredients.
“We are delighted to work with Twist Bioscience to bring the wealth of relevant sequences in our bit-GEM database to not only the biocatalysis community but also the global biomanufacturing community,” said Yuji Suzuki, CEO of bitBiome. “Our companies have complementary strengths, with our database representing a highly diverse collection of sequences unknown to the public domain, and Twist’s capability of making large-scale DNA synthesis possible. We look forward to providing new and innovative solutions for the industry.”
“By mining bitBiome’s massive database and by identifying and synthesizing the enzymes that would be most useful in creating active pharmaceutical ingredients, we can provide our and bitBiome’s customers with a new and robust approach to enzyme engineering and development specific to biocatalysis,” said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “This screening kit builds on our work in DNA synthesis where our customers provide us with sequences and we quickly deliver products. We envision a complementary service wherein customers can not only order specific sequences but also leverage our combined capabilities to identify novel enzymes and protein molecules.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture, and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
About bitBiome, Inc.
bitBiome is a biotechnology company unlocking the full potential of our planet’s microbes to power the future of the bioeconomy. bitBiome’s platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP ®, which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse microbial database of over 2 billion sequences, sourced primarily from environmental samples and containing sequences not present in public databases. Leveraging their expertise in bioinformatics and machine learning, the company also offers a comprehensive enzyme discovery and engineering platform, bit-QED, which encompasses the identification, assessment, and modification of enzymes through wet lab evaluation and directed evolution. bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering sequences and enzymes that cannot be found anywhere else. To learn more about bitBiome’s platform and services, visit www.bitbiome.bio.
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the viability of this product or others as an alternative to conventional chemically synthesized processes used in the manufacturing of small molecule pharmaceuticals, our ability to identify and synthesize the enzymes most useful in creating active pharmaceutical ingredients as well as our ability to provide complementary services for novel enzyme and protein discovery. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805159485/en/
For bitBiome:
info@bitbiome.bio
For Twist:
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: Twist Bioscience Corporation
FAQ
What is the new product launched by Twist Bioscience (TWST) and bitBiome?
How many microbe sequences are in bitBiome's proprietary database used for the TWST collaboration?
What is the main application of the Transaminase Enzyme Screening Kit developed by TWST and bitBiome?
How does the TWST and bitBiome collaboration benefit the pharmaceutical industry?
